NEW YORK (GenomeWeb) – Interpace Diagnostics said after the close of the market on Tuesday that it has entered into a securities purchase deal with certain institutional investors that is expected to raise $3.7 million in net proceeds.

The investors have agreed to purchase 375,000 shares of Interpace's common stock at $6.75 per share, and 255,000 prefunded warrants to purchase common stock at $6.74 per share. The offering is expected to close on or about Jan. 6.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.